Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Support

This activity is supported by educational grants from Genentech, Inc.; Puma Biotechnology, Inc.; and Seattle Genetics Inc.

Community Practice Connections™ How We Do It: Personalizing Treatment for Patients with HER2-Positive Breast Cancer

Release Date: April 30, 2020
Expiration Date: April 30, 2021

Activity Overview

This Community Practice Connections™ How We Do It: Personalizing Treatment for Patients With HER2-Positive Breast Cancer aims to provide practitioners with expert guidance on how to incorporate recent trial data in the treatment of patients with both early and advanced HER2-positive (HER2+) breast cancer, as well as to address clinical scenarios that do not fit neatly into currently available data sets in this therapeutic space. Hear expert commentary from leaders in the field on topics including HER2-targeted agents in early and advanced breast cancer, emerging systemic treatment options for patients with brain metastases, pertinent ongoing clinical trial data, and supportive care strategies for mitigating the effects of adverse events associated with current treatment paradigms.

Acknowledgement of Support

This activity is supported by educational grants from Genentech, Inc.; Puma Biotechnology, Inc.; and Seattle Genetics Inc.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.


Target Audience

This activity is directed toward medical and surgical oncologists who treat patients with breast cancer. Fellows, nurses, nurse practitioners, physician assistants, pathologists, radiation oncologists, and other healthcare professionals (HCPs) involved in the management of patients with breast cancer are also invited to participate.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • Integrate data from recent clinical trials evaluating HER2-targeted agents into personalized treatment algorithms to optimize outcomes for patients with early-stage or advanced/metastatic HER2+ breast cancer
  • Evaluate emerging systemic treatment options for patients with HER2+ breast cancer with brain metastases
  • Discuss ongoing clinical trials investigating novel approaches for HER2+ breast cancer and their potential impact on evolving treatment paradigms for managing HER2+ breast cancer
  • Utilize supportive care strategies for preventing and/or ameliorating treatment-related adverse events in patients receiving HER2-targeted therapy for breast cancer

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Chair

Debu Tripathy, MD
Debu Tripathy, MD
Professor and Chair
Department of Breast Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosures: Grant Research Support: Novartis, Polyphor; Consultant: Novartis, Pfizer, AstraZeneca, GlaxoSmithKline, Genomic Health.

Faculty

Sara A. Hurvitz, MD
Sara A. Hurvitz, MD
Director, Breast Cancer Clinical Research Program
Co-Director, Santa Monica-UCLA Outpatient Hematology/Oncology Practice
Associate Professor of Medicine, Division of Hematology/Oncology
David Geffen School of Medicine at UCLA
Santa Monica, CA

Disclosures: Grant Research Support: Ambrx, Amgen, Arvinas, Bayer, Cascadian Therapeutics, Daiichi Sankyo, Dignitana, Genentech, GlaxoSmithKline, Eli Lilly, MacroGenics, Medivation, Merrimack Pharmaceuticals, Novartis, OBI Pharma, Pfizer, Pieris Pharmaceuticals, Puma Biotechnology, Radius Health, Roche, Seattle Genetics, Immunomedics; Travel: Eli Lilly, Novartis, OBI Pharma.

Joyce A. O’Shaughnessy, MD
Joyce A. O’Shaughnessy, MD
Celebrating Woman Chair in Breast Cancer Research
Baylor University Medical Center
Texas Oncology
Chair, Breast Cancer Research Program, The US Oncology Network
Dallas, TX

Disclosures: Honoraria for consulting and advisory boards: AbbVie, Agendia, Amgen Biotechnology, AstraZeneca, Bristol Myers Squibb, Celgene, Eisai, Genentech, Genomic Health, GRAIL, Immunomedics, Heron Therapeutics, Ipsen Biopharmaceuticals, Jounce Therapeutics, Eli Lilly, Merck, Myriad Genetics, Novartis, Odonate Therapeutics, Pfizer, Puma Biotechnology, Roche, Seattle Genetics, Syndax, Takeda.

Hope S. Rugo, MD, FASCO
Hope S. Rugo, MD, FASCO
Professor of Medicine
Director, Breast Oncology and Clinical Trials Education
University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center
San Francisco, CA

Disclosures: Grant Research Support: Pfizer, Merck, Novartis, Eli Lilly, Genentech, OBI Pharma, Odonate Therapeutics, Daiichi Sankyo, Eisai, Seattle Genetics, MacroGenics, Immunomedics; Travel: Daiichi Sankyo, Mylan, Pfizer, Amgen, Merck, AstraZeneca, MacroGenics, and Puma Biotechnology.

The staff Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.


Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
 123456
78910111213
14151617181920
21222324252627
28293031
Filter By